Relationship between levels of inflammatory markers and the degree of obesity in patients with metabolic syndrome

Currently, metabolic syndrome (MS) is interpreted as a symptom complex of disorders of carbohydrate and lipid metabolism and arterial hypertension. Impaired carbohydrate metabolism or insulin resistance with a decrease in the sensitivity of peripheral tissues to insulin provokes the accumulation of visceral fat, which in turn initiates systemic inflammation. Obesity is clearly associated with cardiovascular pathology with progression of risk and development of diabetes mellitus. Aim is to identify the relationship between traditional markers of inflammation and interleukins -8, -10 with the degree of obesity in patients with MS. Materials and methods: the study included 160 male patients with MS and hypertension. Depending on the degree of obesity, patients were divided into 5 groups: the number of subjects in group 1 (n=36), in group 2 (n=76), in group 3 (n=39), in group 4 (n=6) and in group 5 (n=3). All patients with hypertension of 1-3 degrees, with the target blood pressure level achieved. The age of the subjects was 31-65 years. All patients underwent: collection of complaints and medical history, assessment of body mass index (BMI); determination of lipid spectrum, blood glucose. Microalbuminuria and glomerular filtration rate were determined. Interleukins 8, 10 were determined using the ELISA method. Instrumental studies were performed: ABPM, echocardiography. Results: when assessing traditional risk factors, the following was revealed: a direct relationship between the degree of obesity and BMI (r=0.94; p=0.001), with TG levels (r=0.34; p=0.001), with blood glucose levels (r=0 .24; p=0.004), inverse with MAU (r= -0.92; p=0.003) and direct with SBP level (r=0.35; p=0.0007). Inflammation indicators CRP and ESR were correlated with IL-10 levels, which is associated with activation of anti-inflammatory activity (r=0.83; p=0.01; r=0.78; p=0.02, respectively). Heredity and smoking also determined their contribution to the initiation of inflammation - direct relationships were identified with CRP and fibrinogen levels (r=0.30; p=0.04; r=0.36; p=0.01). Correlation analysis of echocardiography data showed that correlations between LVMI and age were identified (r=0.494; p=0.0001); duration of hypertension (r=0.504; p=0.0001); with blood glucose level (r=0.242; p=0.047).

metabolic syndrome, obesity, arterial hypertension, interleukins-8 -10

1. Koshurnikova A.S., Lukina E. V. Obesity and metabolic syndrome: issues of diagnosis, prevention and treatment. Attending physician. 2017;(10):66. (In Russ.)@@ Кошурникова А. С., Лукина Е. В. Ожирение и метаболический синдром: вопросы диагностики, профилактики и лечения. Лечащий врач. - 2017. - № 10. -. C. 66.

2. Cardiovascular diseases. World Health Organization. Available at: https://www.who.int/news-room/factheets/detail/cardiovascular-diseases-(cvds). - Accessed 17 may 2017.

3. Boytsov S. A., Drapkina O. M., Shlyakhto E. V. et al. Epidemiology of Cardiovascular Diseases and their Risk Factors in Regions of Russian Federation (ESSE-RF) study. Ten years later. Cardiovascular Therapy and Prevention. 2021;20(5):3007. (in Russ.) doi: 10.15829/1728-8800-2021-3007.@@ Бойцов С. А., Драпкина О. М., Шляхто Е. В., Конради А. О., Баланова Ю. А., Жернакова Ю. В., Метельская В. А., Ощепкова Е. В., Ротарь О. П., Шальнова С. А. Исследование ЭССЕ-РФ (Эпидемиология сердечно-сосудистых заболеваний и их факторов риска в регионах Российской Федерации). Десять лет спустя. Кардиоваскулярная терапия и профилактика. 2021;20(5):3007. doi: 10.15829/1728-8800-2021-3007.

4. Chumakova G. A., Veselovskaya N. G., Gritsenko O. V., Ott A. V. Metabolic syndrome: challenging and unresolved issues.Russian Journal of Cardiology. 2014;(3):63-71. (In Russ.) doi: 10.15829/1560-4071-2014-3-63-71.@@ Чумакова Г. А., Веселовская Н. Г., Гриценко О. В., Отт А. В. Mетаболический синдром: сложные и нерешенные проблемы. Российский кардиологический журнал. 2014;(3):63-71. doi: 10.15829/1560-4071-2014-3-63-71.

5. Verbovoy A.F., Verbovaya N. I., Dolgikh Yu. A. Obesity is the basis of metabolic syndrome. Obesity and metabolism. 2021;18(2):142-149. (In Russ.) doi: 10.14341/omet12707.@@ Вербовой А. Ф., Вербовая Н. И., Долгих Ю. А. Ожирение - основа метаболического синдрома. Ожирение и метаболизм. 2021;18(2):142-149. doi: 10.14341/omet12707.

6. Belousova O.N., Chupakha M. V. The influence of subclinical inflammation markers on the development of cardiovascular pathology in patients with metabolic syndrome. Man and his health. 2021;24(2):1-11. (In Russ.) doi: 10.21626/vestnik/2021-2/01.@@ Белоусова О. Н., Чупаха М. В. Влияние маркеров субклинического воспаления на развитие сердечнососудистой патологии у больных с метаболическим синдромом. Человек и его здоровье. 2021;24(2):1-11. doi: 10.21626/vestnik/2021-2/01.

7. Vasyukova O. V., Kasyanova Yu.V., Okorokov P. L., Bezlepkina O. B. Myokines and adipomyokines: inflammatory mediators or unique molecules of targeted therapy for obesity? Problems of Endocrinology. 2021;67(4):36-45. (In Russ.) doi: 10.14341/probl12779.@@ Васюкова О. В., Касьянова Ю. В., Окороков П. Л., Безлепкина О. Б. Миокины и адипомиокины: медиаторы воспаления или уникальные молекулы таргетной терапии ожирения? Проблемы Эндокринологии. 2021;67(4):36-45. doi: 10.14341/probl12779.

8. Shalnova S. A., Maksimov S. A., Balanova Yu.A. et al. Glomerular Filtration Rate, its Association with Risk Factors and Cardiovascular Diseases. The Results of the ESSE-RF-2 Study. Rational Pharmacotherapy in Cardiology. 2020;16(2):240-249. (In Russ.) doi: 10.20996/1819-6446-2020-04-09.@@ Шальнова С. А., Максимов С. А., Баланова Ю. А. и др. Скорость клубочковой фильтрации, ее ассоциации с факторами риска и сердечнососудистыми заболеваниями. Результаты исследования ЭССЕ-РФ-2. Рациональная Фармакотерапия в Кардиологии. 2020;16(2):240-249. doi: 10.20996/1819-6446-2020-04-09.

9. Andrassy K. M.Comments on ‘KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease’. Kidney Int. 2013 Sep.;84(3):622-623.

10. Williams B., Mancia G., Spiering W. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018 Oct;36(10):1953-2041. doi: 10.1097/HJH.0000000000001940.

11. Stergiou G.S., Parati G., Vlachopoulos C. et al. Methodology and technology for peripheral and central blood pressure and blood pressure variability measurement: current status and future directions - Position statement of the European Society of Hypertension Working Group on blood pressure monitoring and cardiovascular variability. J Hypertens. 2016 Sep;34(9):1665-77. doi: 10.1097/HJH.0000000000000969.

12. Yudaeva A. D., Stafeev I. S., Michurina S. S., Menshikov M. Yu., Shestakova M. V., Parfyonova Y. V. The interactions between inflammation and insulin resistance: molecular mechanisms in insulin-producing and insulin-dependent tissues. Diabetes mellitus. 2023;26(1):75-81. (In Russ.) doi: 10.14341/DM12981.@@ Юдаева А. Д., Стафеев Ю. С., Мичурина С. С., Меньшиков М. Ю., Шестакова М. В., Парфенова Е. В. Взаимодействие воспаления и инсулиновой резистентности: молекулярные механизмы в инсулинопродуцирующих и инсулинозависимых тканях. Сахарный диабет. 2023;26(1):75-81. doi: 10.14341/DM12981.

13. Scherbakov V. I., Skosyreva G. A., Ryabichenko T. I., Obukhova O. O. Cytokines and regulation of glucose and lipid metabolism in the obesity. Obesity and metabolism. 2022;19(3):317-323. (In Russ.) doi: 10.14341/omet12863.@@ Щербаков В. И., Скосырева Г. А., Рябиченко Т. И., Обухова О. О. Цитокины и регуляция метаболизма глюкозы и липидов при ожирении. Ожирение и метаболизм. 2022;19(3):317-323. doi: 10.14341/omet12863.

14. Ametov A.S., Pyanykh O. P., Nevolnikova A. O. Modern possibilities for managing metabolic health in patients with obesity and carbohydrate metabolism disorders. Endocrinology: news, opinions, training. 2020;9(1):17-26. (In Russ.) doi: 10.33029/2304-9529-2020-9-1-17-26.@@ Аметов А. С., Пьяных О. П., Невольникова А. О. Современные возможности управления метаболическим здоровьем у пациентов с ожирением и нарушениями углеводного обмена. Эндокринология: новости, мнения, обучение. 2020;9(1):17-26. doi: 10.33029/2304-9529-2020-9-1-17-26.

15. Pavlova Z. Sh., Golodnikov I. I. Obesity = inflammation. Pathogenesis. How does this threaten men? Medical Herald of the South of Russia. 2020;11(4):6-23. (In Russ.) doi: 10.21886/2219-8075-2020-11-4-6-23.@@ Павлова З. Ш., Голодников И. И. Ожирение = воспаление. Патогенез. Чем это грозит мужчинам? Медицинский вестник Юга России. 2020;11(4):6-23. doi: 10.21886/2219-8075-2020-11-4-6-23.

16. Polozova E. I., Puzanova E. V., Seskina A. A. Role of immunological disorders, endothelial dysfunction and hemostatic disorders in the genesis of arterial hypertension in the metabolic syndrome. Medical Immunology (Russia). 2020;22(2):221-230. (In Russ.) doi: 10.15789/1563-0625-ROI-1926.@@ Полозова Э. И., Пузанова Е. В., С. А. А. Роль иммунологических нарушений, эндотелиальной дисфункции и гемостатических расстройств в генезе артериальной гипертензии при метаболическом синдроме. Медицинская иммунология. 2020;22(2):221-230. doi: 10.15789/1563-0625-ROI-1926.